MiMedx Group, Inc. (Nasdaq: MDXG) has announced a strategic realignment aimed at prioritizing the growth of its Wound & Surgical business. 

This realignment involves the immediate suspension of its Knee Osteoarthritis program and the disbanding of its Regenerative Medicine business unit. The objective of this strategic shift is to drive profitability and enhance cash flow generation for the company. 

Additionally, MiMedx has revised its projection for full-year 2023 net sales percentage growth, increasing it from low-double digits to mid-teen. 

Following the announcement, $MDXG is trading at $6.01 in after-hours, reflecting an increase of $.16 (+2.74%).

FedEx Corporation (NYSE: FDX) reported adjusted earnings per share (EPS) for the fourth quarter of fiscal year 2023 as $4.94, with revenue totaling $21.9 billion. These figures differ slightly from the consensus estimate of $4.89 EPS on revenue of $22.67 billion for the same period.

Looking ahead to the full-year fiscal 2024, FedEx is forecasting its adjusted EPS to be in the range of $16.50 to $18.50, while the consensus estimate stands at $18.36.

In after-hours, $FDX is currently trading at $226.09, down $5.56 (-2.40%) 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)